Patents Assigned to DBV Technologies
-
Patent number: 11938178Abstract: The present invention relates to improved epicutaneous administration methods for vaccination of a subject. In particular, the present invention discloses the use of an antigen for epicutaneous immunization, wherein the antigen is administered by epicutaneous application with a skin patch device in combination with an epidermal skin treatment.Type: GrantFiled: July 9, 2019Date of Patent: March 26, 2024Assignees: DBV TECHNOLOGIES, BIONET-ASIA CO., LTDInventors: Hong Thai Pham, Nathalie Donne, Pierre-Louis Herve, Lucie Mondoulet
-
Patent number: 11931411Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: November 10, 2021Date of Patent: March 19, 2024Assignees: DBV Technologies, Assistance Pulique-Hoôpitaux De Paris, Université de Paris CitéInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Publication number: 20220241405Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: November 10, 2021Publication date: August 4, 2022Applicants: DBV Technologies, Assistance Publique-Hôpitaux De Paris, Université De ParisInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Patent number: 11202826Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: July 23, 2020Date of Patent: December 21, 2021Assignees: DBV Technologies, Assistance Publique-Hôpitaux De Paris, Université De ParisInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Patent number: 10881728Abstract: The invention relates to novel compositions and methods for diagnosing or treating food allergies. The invention particularly discloses new approaches for delivering food allergens to allergic patients by oral administration of formulations which dissolve and release proteins in the stomach. The invention allows the treatment of food allergies by delivering food allergens to the gut immune system with controlled exposure of the esophagus or oral cavity. The invention also allows to perform food challenges to assess the threshold of clinical reactivity without exposing the esophagus and oral cavity. The invention may be used in any subject, particularly human subjects, and is applicable to any food allergen.Type: GrantFiled: April 9, 2019Date of Patent: January 5, 2021Assignee: DBV TECHNOLOGIESInventors: Pierre-Henri Benhamou, Christophe Dupont, Stefan (Johan) Koppelman, Laurent Martin, Hervé Brochard, Estelle Foucher
-
Publication number: 20200353072Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: July 23, 2020Publication date: November 12, 2020Applicants: DBV Technologies, Assistance Publique Hopitaux De Paris, Universite Paris DescartesInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Patent number: 10758610Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: April 25, 2019Date of Patent: September 1, 2020Assignees: DBV Technologies, Assistance Publique Hopitaux De Paris, Universite Paris DescartesInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Publication number: 20190314495Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: April 25, 2019Publication date: October 17, 2019Applicants: DBV Technologies, Assistance Publique Hôpitaux De Paris, Université Paris DescartesInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Patent number: 10300133Abstract: The invention relates to novel compositions and methods for diagnosing or treating food allergies. The invention particularly discloses new approaches for delivering food allergens to allergic patients by oral administration of formulations which dissolve and release proteins in the stomach. The invention allows the treatment of food allergies by delivering food allergens to the gut immune system with controlled exposure of the esophagus or oral cavity. The invention also allows to perform food challenges to assess the threshold of clinical reactivity without exposing the esophagus and oral cavity. The invention may be used in any subject, particularly human subjects, and is applicable to any food allergen.Type: GrantFiled: February 3, 2017Date of Patent: May 28, 2019Assignee: DBV TECHNOLOGIESInventors: Pierre-Henri Benhamou, Christophe Dupont, Stefan (Johan) Koppelman, Laurent Martin, Hervé Brochard, Estelle Foucher
-
Patent number: 10272151Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: July 16, 2018Date of Patent: April 30, 2019Assignee: DBV TechnologiesInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Publication number: 20190070286Abstract: The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for improved immunization or vaccination of a subject against a selected pathogen.Type: ApplicationFiled: November 2, 2018Publication date: March 7, 2019Applicant: DBV TECHNOLOGIESInventors: Claire-Anne SIEGRIST, Lucie MONDOULET
-
Publication number: 20180318413Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: July 16, 2018Publication date: November 8, 2018Applicant: DBV TECHNOLOGIESInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Patent number: 10022439Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: December 1, 2016Date of Patent: July 17, 2018Assignee: DBV TechnologiesInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Publication number: 20170128566Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: December 1, 2016Publication date: May 11, 2017Applicant: DBV TECHNOLOGIESInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Patent number: 9539318Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: December 3, 2008Date of Patent: January 10, 2017Assignee: DBV TechnologiesInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Publication number: 20160324955Abstract: The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.Type: ApplicationFiled: June 16, 2016Publication date: November 10, 2016Applicant: DBV TECHNOLOGIESInventors: Pierre-Henri BENHAMOU, Christophe DUPONT, Lucie MONDOULET
-
Patent number: D999384Type: GrantFiled: October 18, 2021Date of Patent: September 19, 2023Assignee: DBV TechnologiesInventors: Pascale Ehouarn, Jérôme Villette
-
Patent number: D999385Type: GrantFiled: October 18, 2021Date of Patent: September 19, 2023Assignee: DBV TechnologiesInventors: Pascale Ehouarn, Jérôme Villette
-
Patent number: D1012296Type: GrantFiled: June 8, 2023Date of Patent: January 23, 2024Assignee: DBV TechnologiesInventors: Pascale Ehouarn, Jérôme Villette
-
Patent number: D1012297Type: GrantFiled: June 8, 2023Date of Patent: January 23, 2024Assignee: DBV TechnologiesInventors: Pascale Ehouarn, Jérôme Villette